180 related articles for article (PubMed ID: 31476483)
1. DTI/DXI interferences with global coagulation tests in emergency hospital admissions - Results of the prospective Dresden NOAC Registry (NCT01588119).
Wunder L; Tittl L; Marten S; Beyer-Westendorf J
Thromb Res; 2019 Oct; 182():101-109. PubMed ID: 31476483
[TBL] [Abstract][Full Text] [Related]
2. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
3. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
5. Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon.
Frans G; Meeus P; Bailleul E
J Thromb Haemost; 2019 Aug; 17(8):1354-1362. PubMed ID: 31102433
[TBL] [Abstract][Full Text] [Related]
6. The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue.
Adcock DM; Gosselin RC
Int J Lab Hematol; 2017 May; 39 Suppl 1():37-40. PubMed ID: 28447415
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
8. Point-of-care testing of coagulation in patients treated with edoxaban.
Härtig F; Birschmann I; Peter A; Hörber S; Ebner M; Sonnleitner M; Spencer C; Bombach P; Stefanou MI; Kuhn J; Mengel A; Ziemann U; Poli S
J Thromb Thrombolysis; 2020 Oct; 50(3):632-639. PubMed ID: 32436010
[TBL] [Abstract][Full Text] [Related]
9. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
[TBL] [Abstract][Full Text] [Related]
11. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR
Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
[TBL] [Abstract][Full Text] [Related]
12. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
Adcock DM; Gosselin R
Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
[TBL] [Abstract][Full Text] [Related]
13. Standardization of coagulation tests.
Opartkiattikul N
Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
[TBL] [Abstract][Full Text] [Related]
14. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
15. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
16. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
[TBL] [Abstract][Full Text] [Related]
17. Coagulation Testing in Intracerebral Hemorrhage Related to Non-vitamin K Antagonist Oral Anticoagulants.
Purrucker JC; Rizos T; Haas K; Wolf M; Khan S; Heuschmann PU; Veltkamp R;
Neurocrit Care; 2017 Oct; 27(2):208-213. PubMed ID: 28477151
[TBL] [Abstract][Full Text] [Related]
18. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
Vercruyssen J; Meeus P; Bailleul E
Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
[TBL] [Abstract][Full Text] [Related]
19. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
[TBL] [Abstract][Full Text] [Related]
20. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
